# Longeveron Inc. Common Stock (LGVN)

> Longeveron Inc. Common Stock (LGVN) trades at $1.66 (-8.79%) as of 7:30:05 PM EST on Nov 20, 2026, +4.40% over the past month. Market cap is $5.6M, with 2.2 days to cover in short interest.

Canonical: https://massive.com/quote/lgvn
Data as of: 2026-11-21T00:30:05.772Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$1.66** -0.16 (-8.79%)
As of 7:30:05 PM EST on Nov 20, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Longeveron Inc. Common Stock (LGVN) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -8.79% |
| 1W | -33.33% |
| 1M | +4.40% |
| YTD | -67.19% |
| 1Y | -73.44% |
| 52-wk range | $1.31 – $12.30 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for LGVN: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $1.64 – $1.83 |
| Open | $1.83 |
| Prev close | $1.82 |
| Volume | 27.26K |
| Market cap | $5.6M |
| Shares out | 3.23M |

## Valuation and profitability ratios

Valuation and profitability ratios for Longeveron Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 4.81 |
| P/B | 1.19 |
| P/FCF | — |
| ROE | -475.3% |
| ROA | -186.3% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 20, 2026

## Insider trading

[Longeveron Inc. Common Stock (LGVN) insider trading](https://massive.com/quote/lgvn/insider-trading.md): open-market Form 4 buys and sells by Longeveron Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Longeveron Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 12, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 12, 2026, Longeveron Inc. (the "Company") issued a press release announcing its financial and operating results for the three and nine months ended September 30, 2026, and certain other business updates and information.”
- Nov 5, 2026 · Director departure
  “On November 1, 2026, Ms. Ursula Ungaro provided Longeveron Inc. (the "Company") with notice of her immediate resignation from the Company's Board of Directors and its Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee, and Special Committee. Ms. Ungaro indicated that her decision to resign was due to personal health issues and not the result of any disagreement with the Company on any matter related to the Company's operations, policies, or practices.”
- Oct 26, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “Longeveron Inc. issued a press release announcing updated results from ELPIS II, its Phase 2b clinical trial evaluating laromestrocel in 40 infants with hypoplastic left heart syndrome. The trial did not meet its primary efficacy endpoint, but the secondary endpoint analysis showed eight major adverse cardiac events in the standard-of-care arm versus one in the laromestrocel arm (P=0.043).”
- Oct 14, 2026 · [Executive officer departure](https://massive.com/quote/sec-filings/8-k/executive-departures.md)
  “On October 7, 2026, Dr. Nataliya Agafonova informed management of Longeveron Inc. of her decision to step down as Chief Medical Officer, to become effective October 14, 2026.”
- Sep 23, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “On September 16, 2026, Longeveron Inc. issued a press release announcing topline results from ELPIS II, its Phase 2b clinical trial evaluating the Company's investigational stem cell therapy, laromestrocel, as an adjunct to Stage 2 palliative surgery in 40 infants with hypoplastic left heart syndrome ("HLHS"). The ELPIS II trial did not meet the primary efficacy endpoint of change from baseline in right ventricular ejection fraction ("RVEF") at Month 12.”

## Dividend history and stock splits

Longeveron Inc. Common Stock's recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-10 · Aug 27, 2026
- 1-for-10 · Mar 27, 2024

## LGVN short interest

How heavily LGVN is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 2.2 |
| Short interest | 157.14K |
| Avg volume | 72.1K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## LGVN news

The latest news and headlines about Longeveron Inc. Common Stock (LGVN).

- [Longeveron Announces 1-for-10 Reverse Stock Split](https://www.globenewswire.com/news-release/2026/08/24/3350096/0/en/longeveron-announces-1-for-10-reverse-stock-split.html) · GlobeNewswire Inc. · Aug 24, 2026 · neutral sentiment
- [Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells](https://www.benzinga.com/pressreleases/26/04/n51754139/biotechs-racing-to-translate-longevity-science-into-real-therapies-and-one-microcap-company-is-pro?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Apr 10, 2026 · positive sentiment
- [A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.](https://www.benzinga.com/pressreleases/26/03/n51325255/a-key-master-protein-that-declines-by-half-after-age-40-one-company-found-a-way-to-restore-it?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Mar 18, 2026 · positive sentiment
- [Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them](https://www.benzinga.com/pressreleases/26/03/n51002127/cell-therapies-moving-from-lab-to-factory-floor-and-the-stocks-behind-them?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Mar 3, 2026 · positive sentiment
- [Longeveron Announces Closing Of Up To $17.5 Million Public Offering](https://www.benzinga.com/pressreleases/25/08/g47043991/longeveron-announces-closing-of-up-to-17-5-million-public-offering) · Benzinga · Aug 11, 2025 · neutral sentiment

## About Longeveron Inc. Common Stock

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 38 |
| Listed | Feb 12, 2021 |

[Company website](https://www.longeveron.com)

## FAQ

### What is the Longeveron Inc. Common Stock (LGVN) stock price today?

Longeveron Inc. Common Stock (LGVN) is trading at $1.66 (-8.79% on the day) as of 7:30:05 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Longeveron Inc. Common Stock?

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel.

### What is the short interest in LGVN?

As of Oct 30, 2026, LGVN has 157.14K shares short and 2.2 days to cover.

### What exchange is LGVN listed on?

Longeveron Inc. Common Stock (LGVN) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time LGVN quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=LGVN`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Longeveron Inc. Common Stock (LGVN) insider trading](https://massive.com/quote/lgvn/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
